SPT-07A injection

Phase 3UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stroke, Acute

Conditions

Stroke, Acute

Trial Timeline

Jan 20, 2022 → Jan 10, 2024

About SPT-07A injection

SPT-07A injection is a phase 3 stage product being developed by Sinopharm for Stroke, Acute. The current trial status is unknown. This product is registered under clinical trial identifier NCT05159947. Target conditions include Stroke, Acute.

What happened to similar drugs?

7 of 20 similar drugs in Stroke, Acute were approved

Approved (7) Terminated (6) Active (9)
StatinShionogiApproved
AlteplaseKyowa KirinApproved
AbciximabEli LillyPhase 3
AbciximabEli LillyPhase 3
🔄Ticagrelor + PlaceboAstraZenecaPhase 3
🔄NXY-059AstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05159947Phase 3UNKNOWN

Competing Products

20 competing products in Stroke, Acute

See all competitors
ProductCompanyStageHype Score
Osmotic drugsSinopharmPre-clinical
33
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
SUN13837 + placeboDaiichi SankyoPhase 2
27
DS-1040b + AspirinDaiichi SankyoPhase 1
29
piclozotan low dose + placebo + piclozotan high doseDaiichi SankyoPhase 2
27
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
40
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
ASP2246Astellas PharmaPhase 1/2
39
Neu2000KWL + Neu2000KWL + Neu2000KWL + PlacebosSun PharmaceuticalPhase 2
35
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
AlteplaseKyowa KirinApproved
43
ONO-2506 + ONO-2506 + ONO-2506Ono PharmaceuticalPhase 2/3
38
AbciximabEli LillyPhase 3
32
AbciximabEli LillyPhase 3
32
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35